DrugPatentWatch Database Preview

Genzyme Company Profile

GENZYME has twelve approved drugs.

There are fourteen US patents protecting GENZYME drugs.

There are three hundred and twelve patent family members on GENZYME drugs in forty-five countries and fifty-four supplementary protection certificates in fourteen countries.

International Patents:	312
US Patents:	14
Tradenames:	11
Ingredients:	11
NDAs:	12
Patent Litigation for Genzyme:	See patent lawsuits for Genzyme

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genzyme	CEREDASE	alglucerase	INJECTABLE;INJECTION	020057-003	Apr 5, 1991		DISCN	No	No		➤ Sign Up				➤ Sign Up
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-001	Jul 12, 2000		RX	Yes	No	6,733,780	➤ Sign Up	Y			➤ Sign Up
Genzyme	CEREZYME	imiglucerase	INJECTABLE;INJECTION	020367-002	Sep 22, 1999		RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-002	Apr 6, 2011		RX	Yes	Yes	8,642,608	➤ Sign Up				➤ Sign Up
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014		RX	Yes	Yes	6,916,802	➤ Sign Up		Y		➤ Sign Up
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-002	Feb 18, 2009	AB	RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genzyme	THYROGEN	thyrotropin alfa	INJECTABLE;INJECTION	020898-001	Nov 30, 1998	5,674,711	➤ Sign Up
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-002	Feb 18, 2009	5,667,775	➤ Sign Up
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009	6,858,203	➤ Sign Up
Genzyme	RENAGEL	sevelamer hydrochloride	CAPSULE;ORAL	020926-001	Oct 30, 1998	5,496,545	➤ Sign Up
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009	7,014,846	➤ Sign Up
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-001	Jul 12, 2000	6,509,013	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	400 mg and 800 mg	➤ Subscribe	2008-05-22
➤ Subscribe	Powder for Oral Suspension	0.8 g/packet and 2.4 g/packet	➤ Subscribe	2009-12-30
➤ Subscribe	Injection	24 mg/1.2 mL vials (20 mg/mL)	➤ Subscribe	2012-12-17
➤ Subscribe	Tablets	800 mg	➤ Subscribe	2008-12-04
➤ Subscribe	Injection	1 mg/mL, 20 mL vial	➤ Subscribe	2012-02-23
➤ Subscribe	Tartrate Capsules	84mg	➤ Subscribe	2018-08-20

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0120014 00064	Estonia	➤ Sign Up	PRODUCT NAME: MOZOBIL - PLERIXAFOR;REG NO/DATE: C(2009)6238 31.07.2009
C038/2009	Ireland	➤ Sign Up	SPC038/2009: 20101001, EXPIRES: 20171215
2015000051	Germany	➤ Sign Up	PRODUCT NAME: ELIGLUSTAT, GGF. IN FORM EINES PHYSIOLOGISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
00428	Netherlands	➤ Sign Up	PRODUCT NAME: SEVELAMER CARBONAAT OF BICARBONAAT; REGISTRATION NO/DATE: EU/1/09/521/001-007 20090610
C/GB12/036	United Kingdom	➤ Sign Up	PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/749/001 20120217; UK EU/1/11/749/002 20120217
717	Luxembourg	➤ Sign Up	PRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.